Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMP-114 in active rheumatoid arthritis
NCT00296257Phase 2Terminated
- Sponsor
- Sumitomo Pharma Europe
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of rimacalib in rheumatoid arthritis (RA) (3 arms), sponsored by Sumitomo Pharma Europe. Primary endpoint: American College of Rheumatology 20% improvement at 24 weeks. Started Feb 2006; status: terminated.
02
Drugs
rimacalib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00296257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00296257.